News
ALNY
146.07
+0.19%
0.28
Weekly Report: what happened at ALNY last week (0415-0419)?
Weekly Report · 1d ago
How Is The Market Feeling About Alnylam Pharmaceuticals?
Alnylam Pharmaceuticals's short percent of float has fallen 9.57% since its last report. The company has 2.80 million shares sold short, which is 2.55% of all regular shares available for trading. Short interest is the number of shares that have been sold short but have not yet been covered.
Benzinga · 4d ago
Health Rounds: Urine tests finds worrisome prostate cancer, avoids unneeded biopsies
Health Rounds: Urine tests finds worrisome prostate cancer, avoids unneeded biopsies. A urine test detects prostate cancer in of treatment more accurately than standard blood tests. A single injection of an experimental drug for people with hard-to-control high blood pressure. The other is a urine test for detecting prostate cancer that may reduce the for biopsy.
Reuters · 5d ago
Guru Fundamental Report for ALNY - Benjamin Graham
NASDAQ · 5d ago
Press Release: Alnylam to Webcast Conference Call Discussing First Quarter 2024 Financial Results
Alnylam to Webcast Conference Call Discussing First Quarter 2024 Financial Results on Thursday, May 2, 2024. The Company will report financial results for the first quarter ending March 31, 2024 before the U.S. Financial markets open. Management will provide an update on the Company and discuss first quarter 2024 results via conference call. Alnylam is the leading RNAi therapeutics company.
Dow Jones · 5d ago
Alnylam Pharmaceuticals, Inc.'s (NASDAQ:ALNY) Path To Profitability
Alnylam Pharmaceuticals, Inc. Posted a loss of US$440m in its most recent financial year. The biopharmaceutical company is expected to grow at an average annual rate of 61% to become profitable. The company is predicted to turn a profit in 2026. It currently has negative equity on its balance sheet. We look at the expectations for the company's growth and when analysts expect it to be profitable.
Simply Wall St · 04/15 11:19
Weekly Report: what happened at ALNY last week (0408-0412)?
Weekly Report · 04/15 09:26
Wolfe upgrades Ionis to outperform, cites upcoming catalysts
Seeking Alpha · 04/10 16:03
Buy Rating Affirmed for Alnylam Pharma on Strong Zilebesiran Trial Results and Lucrative Roche Partnership
TipRanks · 04/09 14:25
Alnylam Pharma Earns Buy Rating on Robust Clinical Trials and Strategic Partnerships
TipRanks · 04/09 11:15
Analysts Have Conflicting Sentiments on These Healthcare Companies: Alnylam Pharma (ALNY), Gilead Sciences (GILD) and Agios Pharma (AGIO)
TipRanks · 04/09 02:50
Analysts Express Confidence in Alnylam's Hypertension Drug Despite Mixed Trial Data
Alnylam Pharmaceuticals Inc. Presented results from the KARDIA-2 Phase 2 study. The company's zilebesiran reduced systolic blood pressure in the primary hypertension market. JMP Securities maintains the Outperform rating on Alnylam and a price target of $217.
Benzinga · 04/08 18:37
Health Care Sector Update for 04/08/2024: ALNY, LEGN, JNJ, NVO, CTLT, XLV, IBB
NASDAQ · 04/08 13:28
Why Alnylam Pharmaceuticals (ALNY) Stock Might be a Great Pick
NASDAQ · 04/08 12:44
Jefferies Keeps Their Buy Rating on Alnylam Pharma (ALNY)
TipRanks · 04/08 12:25
Analysts’ Top Healthcare Picks: Alnylam Pharma (ALNY), ALX Oncology Holdings (ALXO)
TipRanks · 04/08 10:40
Alnylam Pharma (ALNY) Gets a Hold from J.P. Morgan
TipRanks · 04/08 09:51
Weekly Report: what happened at ALNY last week (0401-0405)?
Weekly Report · 04/08 09:28
Reported Sunday, Alnylam Presents Results From The KARDIA-2 Phase 2 Study Of Zilebesiran Added To Standard Of Care Antihypertensives In Patients With Inadequately Controlled Hypertension
Study met primary endpoint of 12.1mmHg blood pressure reduction. Zilebesiran showed significant reductions in blood pressure of up to 12.2 mmHg across three independent study Cohorts. The drug was added to the standard of care for high blood pressure.
Benzinga · 04/08 06:56
ALNYLAM PHARMACEUTICALS INC <ALNY.O> - STUDY MET PRIMARY ENDPOINT
Reuters · 04/07 12:00
More
Webull provides a variety of real-time ALNY stock news. You can receive the latest news about Alnylam Pharmaceuticals Inc through multiple platforms. This information may help you make smarter investment decisions.
About ALNY
Alnylam Pharmaceuticals, Inc. is a clinical-stage company. The Company is engaged in developing mRNA cell therapies for the treatment of autoimmune diseases. The Company’s lead product candidate, Descartes-08, is an autologous mRNA CAR-T directed against the B cell maturation antigen (BCMA). Descartes-08 targets BCMA, which exists on the surface of long-lived plasma cells and plasmacytoid dendritic cells. Descartes-08 is in Phase IIb clinical development for patients with generalized myasthenia gravis (MG). Its other product candidate includes Descartes-15 and Descartes-33. Descartes-15 is a next-generation, autologous anti-BCMA mRNA CAR-T. Using its proprietary technology and manufacturing platform, it designed Descartes-15 to be more resistant than Descartes-08 to recycling of the CAR upon multiple antigen exposures. It is developing Descartes-33 to deliver a combination of therapeutic proteins that target key drivers in the pathogenesis of autoimmunity.